Mr. George Achilleos reports

NETRAMARK SIGNS NEW NETRAAI CLINICAL TRIAL ANALYSIS AGREEMENT WITH LATE-STAGE BIOPHARMACEUTICAL COMPANY

Netramark Holdings Inc. has signed a new agreement with a biopharmaceutical company developing a late-stage central nervous system therapy.

Under the agreement, Netramark will deploy its proprietary NetraAI platform to perform an in-depth analysis of patient-level data from a completed mid-to-late-stage clinical trial. The work will deliver actionable insights to optimize dose selection, enhance patient stratification and inform critical future development decisions.

In addition to dose response, the analysis is intended to generate insights related to treatment efficacy, safety, tolerability, cognition, functional outcomes, discontinuation patterns and patient stratification. Netramark's work is expected to support the new client's internal evaluation of its late-stage clinical development program.

"This agreement marks another important commercial win and reflects the growing momentum behind NetraAI," said George Achilleos, chief executive officer of Netramark. "Our clients are increasingly recognizing that completed clinical trials often contain substantially more information than is captured through conventional analyses. Our proprietary and novel AI platform, NetraAI, is designed to identify clinically interpretable model-derived subgroups, which are compact patient profiles, defined by a small number of variables that can explain dose response, safety and treatment heterogeneity. These insights may help our clients optimize late-stage development programs and make more informed decisions before committing to major late-stage clinical investments."

This agreement represents Netramark's ninth booked commercial contract since the start of its current fiscal year in October, 2025, further demonstrating growing adoption of NetraAI among biopharmaceutical sponsors for late-stage clinical development programs.

The company believes this contract further demonstrates growing interest in artificial-intelligence-enabled clinical trial analytics among biopharmaceutical sponsors. Netramark will continue to pursue opportunities where its platform can support clinical development programs across CNS, oncology and other therapeutic areas.

About Netramark Holdings Inc.

Netramark is focused on being a leader in the development of generative artificial intelligence/machine learning solutions that are targeted at the biotechnology and pharmaceutical industries. The company's product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of machine learning methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets often prevalent in clinical trials and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.